- All News
- In the News
- Press Releases
In the news: Septicyte RAPID test mentioned in Infection Control Today
From the article in Infection Control Today SeptiCyte RAPID test Sepsis is an overwhelming immune response to infection that can be life-threatening. Immunexpress’ SeptiCyte RAPID test is meant to ensure the timely and accurate diagnosis of sepsis, which is critical to allow clinicians to rapidly make correct treatment decisions that...
Immunexpress to Present Data at ECCMID 2023 Indicating that SeptiCyte® RAPID Differentiates Sepsis from Non-Sepsis in Patients with Uncertain Initial Diagnosis
This post originally appeared on Cision PR Newswire SEATTLE and BRISBANE, Australia, April 5, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today a poster presentation at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) which evaluates the use of SeptiCyte® RAPID...
Immunexpress to Present Data at ISICEM 2023 Indicating that SeptiCyte® RAPID Outperforms Other Rapid Measures for Sepsis Diagnosis
New Publication Validates SeptiCyte® RAPID as a Triaging Tool for COVID-19 Patients
SeptiCyte RAPID accurately assessed COVID-19 severity Elevated SeptiScore upon hospital intake was predictive of ICU admission SeptiCyte RAPID performed better than single-biomarker assays that are routinely used to assess COVID-19 severity SEATTLE and BRISBANE, Australia, Feb. 2, 2023 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving...
At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time
From Leo O'Connor of LabPulse.com At the Association for Molecular Pathology annual meeting and exposition this week, Immunexpress launched a rapid molecular diagnostic test that could enable ruling in or ruling out sepsis in one hour. The SeptiCyte Rapid test is different from almost all other sepsis tests on the market by...
A multi-site study confirms the use of undiluted EDTA blood for the SeptiCyte RAPID sepsis assay
Data Validating EDTA Blood as Sample Type for SeptiCyte® RAPID Presented at the Association for Molecular Pathology 2022 Annual Meeting SEATTLE and BRISBANE, Australia, Nov. 3, 2022 /PRNewswire/ -- Immunexpress, Pty Ltd., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today the presentation of an abstract at the Association for...
ContagionLive interview: A Rapid Sepsis Diagnostic Test for Better Patient Outcomes
Nina Cosdon of ContagionLive interviewed the chief medical officer of Immunexpress Inc., Roy Davis, MD, PhD, MHA, in a post titled A Rapid Sepsis Diagnostic Test for Better Patient Outcomes. Sepsis diagnosis often takes days. Dr. Roy Davis and his team have developed a test that can diagnose sepsis in...
CEO Rolland Carlson: When Advancing a Medical Device, Be A Partner First & Seller Second to Hospital Systems
Immunexpress CEO Rolland Carlson was recently featured on HITConsultant, which provides healthcare technology news, analysis and insights for healthcare executives, physicians and providers. "US hospital systems validate the safety, clinical utility, and robustness of newly FDA-approved devices, 510(k) cleared, before adopting them into clinical practice. This work occurs alongside evaluating...
Interview with DocWireNew: Dr. Rollie Carlson, CEO, Immunexpress: Providing RAPID Detection for Sepsis
DocWire News spoke with Dr. Rollie Carlson, CEO of Immunexpress, to learn more about this cutting-edge technology, and how it can quickly and accurately detect sepsis, and lead to faster treatment. https://youtu.be/Vd0FL3fYPwY
Interview with Dr Rolland Carlson and Dr Richard Brandon
Download the Drug Target Review interview with Dr. Rolland Carlson and Dr. Richard Brandon.(pdf) The 2022 Drug Target Review Assays ebook, includes an interview about our sepsis detection initiative. In this collection of articles, Dr. Rolland Carlson and Dr. Richard Brandon, Immunexpress, answer questions about molecular...
If you are a member of the media, please contact: